Because of the promising effects of the checkpoint blockade therapy, such as anti-PD1/PD-L1, on the treatment of human cancer [60], there is considerable interest to revive the function of exhausted T cells by co-blockade of multiple inhibitory receptors simultaneously. This evidence concerns the gene CD274 and cancer.